Delivery Order SPE2DR25D7061-SPE2DR26F7WVB
- Not listed
- The Defense Logistics Agency awarded a $16,543.30 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product, with a completion date of August 21, 2025. This competitive award (no set-aside used) was issued under a firm fixed-price structure and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,687.48 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for ProQuad vials with a completion date of August 29, 2025. This firm fixed-price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationships with DLA for pharmaceutical supply to...
- The Defense Logistics Agency awarded a $2,740.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of November 26, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $6,538.48 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of November 25, 2025. This contract represents a competitively awarded, firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs and is performing the work at its corporate office...
- The Defense Logistics Agency awarded a $1,654.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 20, 2025, with a completion date of September 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The order will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $2,740.40 with an ultimate completion date of August 19, 2025. This firm fixed price, competitively awarded delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,062.32 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 4, 2025. This non-competitive delivery order was issued under a firm fixed-price arrangement and represents a routine pharmaceutical procurement from the DLA Medical Supply Chain. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued against...
- The Defense Logistics Agency awarded a $8,059.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on May 2, 2025, with an ultimate completion date of May 23, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million through December 2026. The work will be performed in Conshohocken, Pennsylvania, where the contractor maintains...
- The Defense Logistics Agency awarded a delivery order valued at $5,480.80 to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product. The contract, issued on September 10, 2025, with an ultimate completion date of October 1, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This award is a child order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $5,062.32 delivery order to AmerisourceBergen Drug Corp for ProQuad vials under a firm fixed-price contract. The delivery order, which has an ultimate completion date of August 21, 2025, was awarded on July 31, 2025, with no set-aside designation. Performance will take place at the contractor's Corporate Office location in Conshohocken, Pennsylvania. ProQuad is a combination vaccine product, and this delivery order represents a routine pharmaceutical...
- SPE2DR25D7061Indefinite Delivery Contract
- SPE2DR25D7061-SPE2DR26F7WVBDelivery Order
The Defense Logistics Agency awarded a $5,012.07 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of January 28, 2026. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is executed under Cencora's substantial $999,999,999 IDC with DLA Troop Support Medical (valued through December 2031), which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen, as a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a broad range of pharmaceutical products and medical supplies to support military treatment facilities and other government healthcare systems. ProQuad vials, a combination vaccine product, fall within the company's extensive portfolio of pharmaceutical commodities delivered through the DLA supply chain. The contract was not designated with a set-aside and was competitively awarded, consistent with AmerisourceBergen's demonstrated capability to meet federal procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 1/5/26 |